Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915208 · ClinicalTrials.gov registry record
Histiocytic Disorder Follow-up Study
A clinical trial of Langerhans Cell Histiocytosis and Histiocytosis, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 6,000
- Enrollment target
- 1
- Study location
NCT05915208 is a study of Langerhans Cell Histiocytosis and Histiocytosis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 6,000 participants, above the 389-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (1442% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05915208, a study of Langerhans Cell Histiocytosis and Histiocytosis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05915208
The ClinicalTrials.gov registry entry for NCT05915208 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 389-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (1442% higher). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 0 interventions.
NCT05915208 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05915208 about?
NCT05915208 is a clinical study titled "Histiocytic Disorder Follow-up Study". The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
What is the current status of trial NCT05915208?
This trial is currently recruiting. The enrollment target is 6,000 participants. The study started on 2022-09-01. Estimated completion is 2028-12.
What conditions does trial NCT05915208 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis, Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, Xanthogranuloma.
Who is sponsoring clinical trial NCT05915208?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05915208 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
RECRUITING · Phase 3
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.